PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Roth Capital Downgrades PTC Therapeutics (PTCT) to Neutral
May 5, 2015 7:05 AM EDTRoth Capital downgraded PTC Therapeutics (NASDAQ: PTCT) from Buy to Neutral with a price target of $63.00 (from $75.00).
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $60.84 yesterday.
... MorePTC Therapeutics (PTCT) Reports Q1 Loss Per Share of $1.15
May 4, 2015 5:02 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.15), may not compare to the analyst estimate of ($1.20). Revenue for the quarter came in at $7.48 million versus the consensus estimate of $2.97 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
... More